Literature DB >> 20155827

Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.

Karin Hellgren1, Karin E Smedby, Nils Feltelius, Eva Baecklund, Johan Askling.   

Abstract

OBJECTIVE: Patients with rheumatoid arthritis (RA), in particular those with the most severe disease, are at increased risk of developing malignant lymphoma. Whether this increase is entirely a consequence of the RA disease and/or its treatment or is reflective of shared susceptibility to the two diseases remains unclear. We undertook this study to assess whether patients with RA are already at increased risk of lymphoma or of other cancers before the diagnosis of RA, and if the relative risk increases with time since RA diagnosis.
METHODS: Patients with incident RA (symptom duration <1 year) (n = 6,745) registered in the Swedish Early Arthritis Registry from 1997 through 2006 were identified. For each patient, 5 general population controls were randomly matched by sex, age, marital status, and residence (n = 33,657). For all study subjects, inclusion in the nationwide Swedish Cancer Register in 1958-2006 was determined. Relative risks (RRs) (with 95% confidence intervals [95% CIs]) of lymphoma and of cancer overall, before and after diagnosis of RA, were estimated using conditional logistic regression and Cox regression, respectively.
RESULTS: Before diagnosis of RA, there was no observed increase in the risk of lymphoma (RR [odds ratio] 0.67 [95% CI 0.37-1.23]) or other cancers (RR 0.78 [95% CI 0.70-0.88]). During the first 10 years following diagnosis of RA, the overall RR (hazard ratio) of lymphoma development was 1.75 (95 % CI 1.04-2.96).
CONCLUSION: These findings indicate that overall, a history of cancer, including lymphoma, does not increase the risk of subsequent RA development. Shared susceptibility to RA and lymphoma may thus be of limited importance. In contrast, increased lymphoma risks were observed within the first decade following RA diagnosis.

Entities:  

Mesh:

Year:  2010        PMID: 20155827     DOI: 10.1002/art.27402

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

Review 1.  Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.

Authors:  Catarina Dias; David A Isenberg
Journal:  Nat Rev Rheumatol       Date:  2011-06       Impact factor: 20.543

2.  Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study.

Authors:  Hai-Long Wang; Yong-Ming Zhou; Guang-Zhao Zhu; Zhu Yang; Bao-Jin Hua
Journal:  Clin Rheumatol       Date:  2017-05-16       Impact factor: 2.980

3.  The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.

Authors:  Yu-Chih Lin; Hui-Wen Chou; Wen-Chan Tsai; Jeng-Hsien Yen; Shun-Jen Chang; Yi-Ching Lin
Journal:  Clin Rheumatol       Date:  2015-05-20       Impact factor: 2.980

4.  No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan.

Authors:  Wen-Kuan Huang; Meng-Jiun Chiou; Chang-Fu Kuo; Yung-Chang Lin; Kuang-Hui Yu; Lai-Chu See
Journal:  Rheumatol Int       Date:  2014-03-27       Impact factor: 2.631

5.  Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.

Authors:  Francisco Silva; Philip Seo; Darrell R Schroeder; John H Stone; Peter A Merkel; Gary S Hoffman; Robert Spiera; Jodi K Sebastian; John C Davis; E William St Clair; Nancy B Allen; W Joseph McCune; Steven R Ytterberg; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2011-08

Review 6.  Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.

Authors:  Alexis L Franks; Jill E Slansky
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

Review 7.  The risk of malignancies in RA patients treated with biologics.

Authors:  J Askling
Journal:  Z Rheumatol       Date:  2010-11       Impact factor: 1.372

Review 8.  Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?

Authors:  George E Fragoulis; Katerina Chatzidionysiou
Journal:  Clin Rheumatol       Date:  2019-12-13       Impact factor: 2.980

9.  The Role of Tumor Necrosis Factor Alpha (TNFα)in Hearing Loss and Vestibular Schwannomas.

Authors:  Yin Ren; Konstantina M Stankovic
Journal:  Curr Otorhinolaryngol Rep       Date:  2018-02-17

Review 10.  Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Authors:  Gerd R Burmester; Remo Panaccione; Kenneth B Gordon; Melissa J McIlraith; Ana P M Lacerda
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.